Trial Profile
Phase II, Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) in Children and Adults With Neuroendocrine and Other Somatostatin Receptor Expressing Tumors
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Gallium 68-DOTATOC (Primary) ; Yttrium-90-DOTATOC (Primary) ; Amino acids
- Indications Medulloblastoma; Meningioma; Neuroblastoma; Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 23 Aug 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 09 Jan 2017 New trial record